Stock Taper
NCNA
NUCANA PLC
NASDAQ
$1.76
▲ UP 19.73% (0.29)

KEY STATISTICS

Market Cap$10.69 M
52w High$7.22
52w Low$1.21
Dividend Yield
Frequency
P/E-0.59
Volume946.32K
Shares Out.6.07M

COMPANY

LEADERSHIP

Hugh Stephen Griffith
CHIEF EXECUTIVE
Hugh Stephen Griffith

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 28, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
11

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2025-08-08Reverse1:200
2024-04-16Reverse1:25

PRICE

$1.76 ▲ UP 19.73% (+$0.29)
OVERLAYS
$1.50$1.60$1.7010:07 AM11:06 AM12:04 PM1:03 PM2:02 PM3:00 PM3:59 PM1.76

About NuCana plc

https://www.nucana.com ↗

NuCana plc is a UK-based clinical-stage biopharma developing cancer treatments using its proprietary ProTide technology, with lead candidates like Acelarin and NUC-3373 in various clinical trial phases.

INDUSTRY

Biotechnology

A PRODUCT NUCANA PLC IS KNOWN FOR

NUC-7738
NUC-7738

A clinical-stage anti-cancer agent developed using NuCana's proprietary ProTide technology. It is currently in a Phase 1/2 study for advanced solid tumors and melanoma, representing the company's most prominent and actively advancing drug candidate.

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

DIRECTOR
Levy Elliott M.
Sale · 23.8M shares
2026-06-19
OFFICER: CHIEF MEDICAL OFFICER
Bloss Jeffrey D.
Sale · 36.5M shares
2026-06-19
OFFICER: CHIEF OPERATING OFFICER
Bruce Theresa Margaret Ms
Purchase · 132.6M shares
2026-04-15
DIRECTOR
Levy Elliott M.
· —
2026-03-18

SECTORS PEERS

PEERPRICE
PTHS$24.73COMPARE
ENLV$1.35COMPARE
LSTA$1.69COMPARE
NRSN$0.42COMPARE
PASG$4.52COMPARE
GDTC$0.92COMPARE
CLGN$0.36COMPARE
MTVA$1.70COMPARE